Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study

Eur J Clin Microbiol Infect Dis. 2022 Dec;41(12):1473-1477. doi: 10.1007/s10096-022-04513-5. Epub 2022 Oct 25.

Abstract

This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked data on an individual level using a unique personal identifier. A total of 948,263 individuals were included and followed between June 15, 2020, and September 18, 2021 (58.6% were vaccinated during follow-up). The adjusted vaccine effectiveness was 42% (95% confidence interval (CI): 9-63%) for all-serotype IPD and 58% (95% CI: 21-78%) for PPV23-serotype IPD, using no vaccination as the reference.

Keywords: Epidemiology; Invasive pneumococcal disease; Pneumococcal polysaccharide vaccine; Vaccine effectiveness.

MeSH terms

  • Cohort Studies
  • Denmark / epidemiology
  • Humans
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines*
  • Serogroup

Substances

  • Pneumococcal Vaccines